JCR Pharmaceuticals Co., Ltd.
FY March 2026 Q3 Earnings Presentation
For the third quarter of FY March 2026, net sales were 30,353 million yen, a 17.3% increase year-over-year. Operating income turned positive to 427 million yen. Full-year earnings guidance was revised to net sales of 39,500 million yen and operating income of 400 million yen.
Key Figures
- Net Sales: 30,353 million yen (Year-over-Year +17.3%)
- Operating Income: 427 million yen (Previous period was a loss of -754 million yen)
- Net Income Attributable to Owners of Parent (Quarter): 1,744 million yen (Previous period was a loss of -576 million yen)
AI要約
Performance Overview
For the third quarter of FY March 2026, consolidated net sales increased 17.3% year-over-year to 30,353 million yen. Gross profit rose 25.0% to 23,585 million yen. Operating income turned positive to 427 million yen, aided also by foreign exchange gains recorded as non-operating income. R&D expenses increased 34.7% due to recognition of contract upfront payments. Extraordinary profit rose 96.4% due to the recording of subsidy income. Net income attributable to owners of parent for the quarter was 1,744 million yen, marking a significant improvement from a loss in the same period last year.
Revision of Full-year Earnings Forecast and Outlook
The full-year consolidated earnings forecast was revised upward for net sales to 39,500 million yen but downward for operating income by 2,200 million yen to 400 million yen. The downward revision in operating income reflects increased cost of sales and selling, general and administrative expenses. R&D expenses were revised upward by 1,500 million yen due to contract upfront payments related to obtaining exclusive licenses. Net sales growth is expected to be driven by increased demand for renal anemia and Fabry disease treatments. Going forward, the company will focus on the development and commercialization of the new therapeutic agent Givinostat and aims to expand its portfolio of rare disease treatments.
